<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZOSYN  PHARMACY BULK PACKAGE- tazobactam sodium and piperacillin sodium injection, powder, lyophilized, for solution </strong><br>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.<br></p></div>
<h1>ZOSYN<span class="Sup">®</span><br> (Piperacillin and Tazobactam for Injection, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<table width="50%">
<col align="center" valign="top" width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule" align="center"><span class="Bold">Pharmacy Bulk Package<br>Not for Direct Infusion</span></td></tr></tbody>
</table>
<p class="First"><span class="Bold">RECONSTITUTED STOCK SOLUTION MUST BE TRANSFERRED AND FURTHER DILUTED FOR I.V. INFUSION</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZOSYN<span class="Sup">®</span> (piperacillin and tazobactam) injection and other antibacterial drugs, ZOSYN (piperacillin and tazobactam) should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>Package</h2>
<p class="First">The PHARMACY BULK VIAL is a container of sterile preparation which contains many single doses for parenteral use. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Product</h2>
<p class="First">ZOSYN (piperacillin and tazobactam for injection, USP) is an injectable antibacterial combination product consisting of the semisynthetic antibiotic piperacillin sodium and the β-lactamase inhibitor tazobactam sodium for intravenous administration.</p>
<p>Piperacillin sodium is derived from D(-)-α-aminobenzyl-penicillin. The chemical name of piperacillin sodium is sodium (2<span class="Italics">S</span>,5<span class="Italics">R</span>,6<span class="Italics">R</span>)-6-[(<span class="Italics">R</span>)-2-(4-ethyl-2,3-dioxo-1-piperazine- carboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane- 2-carboxylate. The chemical formula is C<span class="Sub">23</span>H<span class="Sub">26</span>N<span class="Sub">5</span>NaO<span class="Sub">7</span>S and the molecular weight is 539.5. The chemical structure of piperacillin sodium is:</p>
<div class="Figure"><img alt="Chemical Structure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81b0bb45-ce9d-43e7-b181-64315e14be55&amp;name=zosyn-01.jpg"></div>
<p>Tazobactam sodium, a derivative of the penicillin nucleus, is a penicillanic acid sulfone. Its chemical name is sodium (2<span class="Italics">S</span>,3<span class="Italics">S</span>,5<span class="Italics">R</span>)-3-methyl-7-oxo-3-(1<span class="Italics">H</span>-1,2,3-triazol-1-ylmethyl)-4-thia- 1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide. The chemical formula is C<span class="Sub">10</span>H<span class="Sub">11</span>N<span class="Sub">4</span>NaO<span class="Sub">5</span>S and the molecular weight is 322.3. The chemical structure of tazobactam sodium is:</p>
<div class="Figure"><img alt="Chemical Structure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81b0bb45-ce9d-43e7-b181-64315e14be55&amp;name=zosyn-02.jpg"></div>
<p>ZOSYN, piperacillin/tazobactam parenteral combination, is a white to off-white sterile, cryodesiccated powder consisting of piperacillin and tazobactam as their sodium salts packaged in glass vials. The formulation also contains 9 mg of edetate disodium dihydrate (EDTA) and sodium citrate.</p>
<p>Each ZOSYN 40.5 g pharmacy bulk vial contains piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 g of tazobactam sufficient for delivery of multiple doses.</p>
<p>ZOSYN is a monosodium salt of piperacillin and a monosodium salt of tazobactam containing a total of 2.79 mEq (64 mg) of Na<span class="Sup">+</span> per gram of piperacillin in the combination product.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinpharm"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Adults</h2>
<p class="First">Peak plasma concentrations of piperacillin and tazobactam are attained immediately after completion of an intravenous infusion of ZOSYN (piperacillin and tazobactam for injection, USP). Piperacillin plasma concentrations, following a 30-minute infusion of ZOSYN (piperacillin and tazobactam for injection, USP), were similar to those attained when equivalent doses of piperacillin were administered alone, with mean peak plasma concentrations of approximately 134 μg/mL, 242 μg/mL, and 298 μg/mL for the 2.25 g, 3.375 g, and 4.5 g ZOSYN (piperacillin and tazobactam for injection, USP) doses, respectively. The corresponding mean peak plasma concentrations of tazobactam were 15 μg/mL, 24 μg/mL, and 34 μg/mL, respectively.</p>
<p>Following a 30-minute I.V. infusion of 3.375 g ZOSYN (piperacillin and tazobactam for injection, USP) every 6 hours, steady-state plasma concentrations of piperacillin and tazobactam were similar to those attained after the first dose. In like manner, steady-state plasma concentrations were not different from those attained after the first dose when 2.25 g or 4.5 g doses of ZOSYN (piperacillin and tazobactam for injection, USP) were administered via 30-minute infusions every 6 hours. Steady-state plasma concentrations after 30-minute infusions every 6 hours are provided in <span class="Bold">Table 1</span>.</p>
<p>Following single or multiple ZOSYN doses to healthy subjects, the plasma half-life of piperacillin and of tazobactam ranged from 0.7 to 1.2 hours and was unaffected by dose or duration of infusion.</p>
<p>Piperacillin is metabolized to a minor microbiologically active desethyl metabolite. Tazobactam is metabolized to a single metabolite that lacks pharmacological and antibacterial activities. Both piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion. Piperacillin is excreted rapidly as unchanged drug with 68% of the administered dose excreted in the urine. Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the administered dose excreted as unchanged drug and the remainder as the single metabolite. Piperacillin, tazobactam, and desethyl piperacillin are also secreted into the bile.</p>
<p>Both piperacillin and tazobactam are approximately 30% bound to plasma proteins. The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound. Protein binding of the tazobactam metabolite is negligible.</p>
<p>Piperacillin and tazobactam are widely distributed into tissues and body fluids including intestinal mucosa, gallbladder, lung, female reproductive tissues (uterus, ovary, and fallopian tube), interstitial fluid, and bile. Mean tissue concentrations are generally 50% to 100% of those in plasma. Distribution of piperacillin and tazobactam into cerebrospinal fluid is low in subjects with non-inflamed meninges, as with other penicillins.</p>
<p>After the administration of single doses of piperacillin/tazobactam to subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the half-life of piperacillin and of tazobactam increases with decreasing creatinine clearance. At creatinine clearance below 20 mL/min, the increase in half-life is twofold for piperacillin and fourfold for tazobactam compared to subjects with normal renal function. Dosage adjustments for ZOSYN are recommended when creatinine clearance is below 40 mL/min in patients receiving the usual recommended daily dose of ZOSYN. (See <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span> section for specific recommendations for the treatment of patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.)</p>
<p>Hemodialysis removes 30% to 40% of a piperacillin/tazobactam dose with an additional 5% of the tazobactam dose removed as the tazobactam metabolite. Peritoneal dialysis removes approximately 6% and 21% of the piperacillin and tazobactam doses, respectively, with up to 16% of the tazobactam dose removed as the tazobactam metabolite. For dosage recommendations for patients undergoing hemodialysis, see <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span> section.</p>
<p>The half-life of piperacillin and of tazobactam increases by approximately 25% and 18%, respectively, in patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> compared to healthy subjects. However, this difference does not warrant dosage adjustment of ZOSYN due to <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>.</p>
<a name="table1"></a><table width="75%">
<caption><span>TABLE 1 STEADY STATE MEAN PLASMA CONCENTRATIONS IN ADULTS AFTER 30-MINUTE INTRAVENOUS INFUSION OF PIPERACILLIN/TAZOBACTAM EVERY 6 HOURS</span></caption>
<col align="left" valign="top" width="17%">
<col align="left" valign="top" width="17%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="13%">
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Numbers in parentheses are coefficients of variation (CV%).</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Piperacillin and tazobactam were given in combination.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>N = 4</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>N = 3</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First"><td align="center" colspan="9"><span class="Bold">PIPERACILLIN</span></td></tr>
<tr class="Botrule">
<td align="left"></td>
<td align="left"></td>
<td align="center" colspan="6" valign="bottom">Plasma Concentrations<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> (μg/mL)</td>
<td align="center">AUC<a href="#footnote-1" class="Sup">*</a><br>(μg•hr/mL)</td>
</tr>
<tr class="Botrule">
<td align="left">Piperacillin/<br>Tazobactam Dose<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="left">No. of Evaluable Subjects</td>
<td align="center" valign="bottom">30 min</td>
<td align="center" valign="bottom">1 hr</td>
<td align="center" valign="bottom">2 hr</td>
<td align="center" valign="bottom">3 hr</td>
<td align="center" valign="bottom">4 hr</td>
<td align="center" valign="bottom">6 hr</td>
<td align="center" valign="bottom">AUC<span class="Sub">0–6</span>
</td>
</tr>
<tr>
<td align="left">2.25 g</td>
<td align="left">8</td>
<td align="center">134 (14)</td>
<td align="center">57 (14)</td>
<td align="center">17.1 (23)</td>
<td align="center">5.2 (32)</td>
<td align="center">2.5 (35)</td>
<td align="center">0.9 (14)<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td align="center">131 (14)</td>
</tr>
<tr>
<td align="left">3.375 g</td>
<td align="left">6</td>
<td align="center">242 (12)</td>
<td align="center">106 (8)</td>
<td align="center">34.6 (20)</td>
<td align="center">11.5 (19)</td>
<td align="center">5.1 (22)</td>
<td align="center">1.0 (10)</td>
<td align="center">242 (10)</td>
</tr>
<tr class="Botrule">
<td align="left">4.5 g</td>
<td align="left">8</td>
<td align="center">298 (14)</td>
<td align="center">141 (19)</td>
<td align="center">46.6 (28)</td>
<td align="center">16.4 (29)</td>
<td align="center">6.9 (29)</td>
<td align="center">1.4 (30)</td>
<td align="center">322 (16)</td>
</tr>
<tr class="Botrule"><td align="center" colspan="9"><span class="Bold">TAZOBACTAM</span></td></tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="center" colspan="6" valign="bottom">Plasma Concentrations<a href="#footnote-1" class="Sup">*</a> (μg/mL)</td>
<td align="center">AUC<a href="#footnote-1" class="Sup">*</a><br>(μg•hr/mL)</td>
</tr>
<tr class="Botrule">
<td align="left">Piperacillin/<br>Tazobactam Dose<a href="#footnote-2" class="Sup">†</a>
</td>
<td align="left">No. of Evaluable Subjects</td>
<td align="center" valign="bottom">30 min</td>
<td align="center" valign="bottom">1 hr</td>
<td align="center" valign="bottom">2 hr</td>
<td align="center" valign="bottom">3 hr</td>
<td align="center" valign="bottom">4 hr</td>
<td align="center" valign="bottom">6 hr</td>
<td align="center" valign="bottom">AUC<span class="Sub">0–6</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">2.25 g</td>
<td align="left" valign="bottom">8</td>
<td align="center">14.8 (14)</td>
<td align="center">7.2 (22)</td>
<td align="center">2.6 (30)</td>
<td align="center">1.1 (35)</td>
<td align="center">0.7 (6)<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td align="center">&lt;0.5</td>
<td align="center">16.0 (21)</td>
</tr>
<tr>
<td align="left" valign="bottom">3.375 g</td>
<td align="left" valign="bottom">6</td>
<td align="center">24.2 (14)</td>
<td align="center">10.7 (7)</td>
<td align="center">4.0 (18)</td>
<td align="center">1.4 (21)</td>
<td align="center">0.7 (16)<a href="#footnote-3" class="Sup">‡</a>
</td>
<td align="center">&lt;0.5</td>
<td align="center">25.0 (8)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="bottom">4.5 g</td>
<td align="left" valign="bottom">8</td>
<td align="center">33.8 (15)</td>
<td align="center">17.3 (16)</td>
<td align="center">6.8 (24)</td>
<td align="center">2.8 (25)</td>
<td align="center">1.3 (30)</td>
<td align="center">&lt;0.5</td>
<td align="center">39.8 (15)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Pediatrics</h2>
<p class="First">Piperacillin and tazobactam pharmacokinetics were studied in pediatric patients 2 months of age and older. The clearance of both compounds is slower in the younger patients compared to older children and adults.</p>
<p>In a population PK analysis, estimated clearance for 9 month-old to 12 year-old patients was comparable to adults, with a population mean (SE) value of 5.64 (0.34) mL/min/kg. The piperacillin clearance estimate is 80% of this value for pediatric patients 2 – 9 months old. In patients younger than 2 months of age, clearance of piperacillin is slower compared to older children; however, it is not adequately characterized for dosing recommendations. The population mean (SE) for piperacillin distribution volume is 0.243 (0.011) L/kg and is independent of age.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.3"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. <span class="Italics">In vitro</span>, piperacillin is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria. Tazobactam sodium has little clinically relevant <span class="Italics">in vitro</span> activity against bacteria due to its reduced affinity to penicillin-binding proteins. It is, however, a β-lactamase inhibitor of the Richmond-Sykes class III (Bush class 2b &amp; 2b') penicillinases and cephalosporinases. It varies in its ability to inhibit class II and IV (2a &amp; 4) penicillinases. Tazobactam does not induce chromosomally-mediated β-lactamases at tazobactam concentrations achieved with the recommended dosage regimen.</p>
<p>Piperacillin/tazobactam has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#indications">INDICATIONS AND USAGE</a></span> section.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.1"></a><p></p>
<h3>Aerobic and facultative gram-positive microorganisms</h3>
<p class="First"><span class="Italics">Staphylococcus aureus</span> (excluding methicillin and oxacillin-resistant isolates)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.2"></a><p></p>
<h3>Aerobic and facultative gram-negative microorganisms</h3>
<p class="First"><span class="Italics">Acinetobacter baumanii</span><br><span class="Italics">Escherichia coli</span><br><span class="Italics">Haemophilus influenzae</span> (excluding β-lactamase negative, ampicillin-resistant isolates)<br><span class="Italics">Klebsiella pneumoniae</span><br><span class="Italics">Pseudomonas aeruginosa</span> (given in combination with an aminoglycoside to which the isolate is susceptible)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.3"></a><p></p>
<h3>Gram-negative anaerobes</h3>
<p class="First"><span class="Italics">Bacteroides fragilis</span> group (<span class="Italics">B. fragilis, B. ovatus, B. thetaiotaomicron,</span> and <span class="Italics">B. vulgatus</span>)</p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Bold Underline">but their clinical significance is unknown</span>.</p>
<p>At least 90% of the following microorganisms exhibit <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoint for piperacillin/tazobactam. However, the safety and effectiveness of piperacillin/tazobactam in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria have not been established in adequate and well-controlled clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.4"></a><p></p>
<h3>Aerobic and facultative gram-positive microorganisms</h3>
<p class="First"><span class="Italics">Enterococcus faecalis</span> (ampicillin or penicillin-susceptible isolates only)<br><span class="Italics">Staphylococcus epidermidis</span> (excluding methicillin and oxacillin-resistant isolates)<br><span class="Italics">Streptococcus agalactiae</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">1</a><br><span class="Italics">Streptococcus pneumoniae</span><a href="#footnote-5" class="Sup">1</a> (penicillin-susceptible isolates only)<br><span class="Italics">Streptococcus pyogenes</span><a href="#footnote-5" class="Sup">1</a><br>Viridans group streptococci<a href="#footnote-5" class="Sup">1</a></p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">1</a></dt>
<dd>These are not β-lactamase producing bacteria and, therefore, are susceptible to piperacillin alone.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.5"></a><p></p>
<h3>Aerobic and facultative gram-negative microorganisms</h3>
<p class="First"><span class="Italics">Citrobacter koseri<br>Moraxella catarrhalis<br>Morganella morganii<br>Neisseria gonorrhoeae<br>Proteus mirabilis<br>Proteus vulgaris<br>Serratia marcescens<br>Providencia stuartii<br>Providencia rettgeri<br><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> enterica</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.6"></a><p></p>
<h3>Gram-positive anaerobes</h3>
<p class="First"><span class="Italics">Clostridium perfringens</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.7"></a><p></p>
<h3>Gram-negative anaerobes</h3>
<p class="First"><span class="Italics">Bacteroides distasonis<br>Prevotella melaninogenica</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Susceptibility Testing Methods</h2>
<p class="First">As is recommended with all antimicrobials, the results of <span class="Italics">in vitro</span> susceptibility tests, when available, should be provided to the physician as periodic reports, which describe the susceptibility profile of nosocomial and community–acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.1"></a><p></p>
<h3>Dilution Techniques</h3>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of piperacillin and tazobactam powders.<span class="Sup">1,2</span> MIC values should be determined using serial dilutions of piperacillin combined with a fixed concentration of 4 μg/mL tazobactam. The MIC values obtained should be interpreted according to criteria provided in <span class="Bold">Table 2</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.2"></a><p></p>
<h3>Diffusion Technique</h3>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">1,3</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 100 μg of piperacillin and 10 μg of tazobactam to test the susceptibility of microorganisms to piperacillin/tazobactam. The disk diffusion interpreted criteria are provided in <span class="Bold">Table 2</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5"></a><p></p>
<h2>Anaerobic Techniques</h2>
<p class="First">For anaerobic bacteria, the susceptibility to piperacillin/tazobactam can be determined by the reference agar dilution method.<span class="Sup">4</span></p>
<a name="table2"></a><table width="75%">
<caption><span>TABLE 2 SUSCEPTIBILITY INTERPRETIVE CRITERIA FOR PIPERACILLIN/TAZOBACTAM</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="6">Susceptibility Test Result Interpretive Criteria</th>
</tr>
<tr>
<th align="left"></th>
<th align="center" colspan="3">Minimal Inhibitory Concentration<br>(MIC in μg/mL)</th>
<th align="center" colspan="3">Disk Diffusion <br>(Zone Diameter in mm)</th>
</tr>
<tr class="Last">
<th align="left">Pathogen</th>
<th align="center">S</th>
<th align="center">I</th>
<th align="center">R</th>
<th align="center">S</th>
<th align="center">I</th>
<th align="center">R</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>These interpretive criteria for <span class="Italics">Haemophilus influenzae</span> are applicable only to tests performed using Haemophilus Test Medium inoculated with a direct colony suspension and incubated at 35°C in ambient air for 20 to 24 hours.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">
<span class="Italics">Enterobacteriaceae</span> and <span class="Italics">Acinetobacter baumanii</span>
</td>
<td align="center">≤ 16</td>
<td align="center">32 – 64</td>
<td align="center">≥ 128</td>
<td align="center">≥ 21</td>
<td align="center">18 – 20</td>
<td align="center">≤ 17</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Haemophilus influenzae</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</td>
<td align="center">≤ 1</td>
<td align="center">-</td>
<td align="center">≥ 2</td>
<td align="center">≥ 21</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left"><span class="Italics">Pseudomonas aeruginosa</span></td>
<td align="center">≤ 64</td>
<td align="center">-</td>
<td align="center">≥ 128</td>
<td align="center">≥ 18</td>
<td align="center">-</td>
<td align="center">≤ 17</td>
</tr>
<tr>
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="center">≤ 8</td>
<td align="center">-</td>
<td align="center">≥ 16</td>
<td align="center">≥ 18</td>
<td align="center">-</td>
<td align="center">≤ 17</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">Bacteroides fragilis</span> group</td>
<td align="center">≤ 32</td>
<td align="center">64</td>
<td align="center">≥ 128</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
</tbody>
</table>
<p>A report of S ("Susceptible") indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of I ("Intermediate") indicates that the results should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone, which prevents small, uncontrolled technical factors from causing major discrepancies in interpretation. A report of R ("Resistant") indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6"></a><p></p>
<h2>Quality Control</h2>
<p class="First">Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the test procedures.<span class="Sup">1,2,3,4</span> Standard piperacillin/tazobactam powder should provide the following ranges of values noted in <span class="Bold">Table 3</span>. Quality control microorganisms are specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of microorganisms with intrinsic biological properties relating to resistance mechanisms and their genetic expression within the microorganism; the specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> used for microbiological quality control are not clinically significant.</p>
<a name="table3"></a><table width="75%">
<caption><span>TABLE 3 ACCEPTABLE QUALITY CONTROL RANGES FOR PIPERACILLIN/TAZOBACTAM TO BE USED IN VALIDATION OF SUSCEPTIBILITY TEST RESULTS</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="bottom" width="33%">
<col align="center" valign="bottom" width="34%">
<thead>
<tr class="Botrule First">
<th align="left"></th>
<th align="center" colspan="2">Acceptable Quality Control Ranges</th>
</tr>
<tr>
<th align="left"></th>
<th align="center"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentration</span></th>
<th align="center">Disk Diffusion</th>
</tr>
<tr class="Last">
<th align="left" valign="bottom">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></th>
<th align="center">Range (MIC in μg/mL)</th>
<th align="center">Zone Diameter Ranges in mm</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>This quality control range for <span class="Italics">Haemophilus influenzae</span> is applicable only to tests performed using Haemophilus Test Medium inoculated with a direct colony suspension and incubated at 35°C in ambient air for 20 to 24 hours.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>The quality control ranges for <span class="Italics">Bacteroides fragilis</span> and <span class="Italics">Bacteroides thetaiotaomicron</span> are applicable only to tests performed using the agar dilution method.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">
<span class="Italics">Escherichia coli</span><br>ATCC 25922</td>
<td align="center">1 – 4</td>
<td align="center">24 – 30</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Escherichia coli</span><br>ATCC 35218</td>
<td align="center">0.5 – 2</td>
<td align="center">24 – 30</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Pseudomonas aeruginosa</span><br>ATCC 27853</td>
<td align="center">1 – 8</td>
<td align="center">25 – 33</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Haemophilus influenzae</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a><br>ATCC 49247</td>
<td align="center">0.06 – 0.5</td>
<td align="center">33–38</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Staphylococcus aureus</span><br>ATCC 29213</td>
<td align="center">0.25 – 2</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Staphylococcus aureus</span><br>ATCC 25923</td>
<td align="center">-</td>
<td align="center">27 – 36</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Bacteroides fragilis<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a></span><br>ATCC 25285</td>
<td align="center">0.12 – 0.5</td>
<td align="center">-</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">Bacteroides thetaiotaomicron</span><a href="#footnote-8" class="Sup">†</a><br>ATCC 29741</td>
<td align="center">4 – 16</td>
<td align="center">-</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indications"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ZOSYN (piperacillin and tazobactam for injection, USP) is indicated for the treatment of patients with moderate to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by piperacillin-resistant, piperacillin/tazobactam-susceptible, β-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the specified conditions listed below:</p>
<p><span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">Appendicitis</span> (complicated by rupture or <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>) and <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> caused by piperacillin-resistant, β-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli</span> or the following members of the <span class="Italics">Bacteroides fragilis</span> group: <span class="Italics">B. fragilis</span>, <span class="Italics">B. ovatus</span>, <span class="Italics">B. thetaiotaomicron,</span> or <span class="Italics">B. vulgatus</span>. The individual members of this group were studied in less than 10 cases.</p>
<p>Uncomplicated and complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, cutaneous <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, and ischemic/<span class="product-label-link" type="condition" conceptid="4087682" conceptname="Diabetic foot">diabetic foot</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by piperacillin-resistant, β-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Staphylococcus aureus</span>.</p>
<p>Postpartum <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span> or <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by piperacillin-resistant, β-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli</span>.</p>
<p>Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (moderate severity only) caused by piperacillin-resistant, β-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Haemophilus influenzae</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial pneumonia</span> (moderate to severe) caused by piperacillin-resistant, β-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Staphylococcus aureus</span> and by piperacillin/tazobactam-susceptible <span class="Italics">Acinetobacter baumanii</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Klebsiella pneumoniae</span>, and <span class="Italics">Pseudomonas aeruginosa</span> (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial pneumonia</span> caused by <span class="Italics">P. aeruginosa</span> should be treated in combination with an aminoglycoside). (See <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>ZOSYN (piperacillin and tazobactam for injection, USP) is indicated only for the specified conditions listed above. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by piperacillin-susceptible organisms, for which piperacillin has been shown to be effective, are also amenable to ZOSYN treatment due to its piperacillin content. The tazobactam component of this combination product does not decrease the activity of the piperacillin component against piperacillin-susceptible organisms. Therefore, the treatment of mixed <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by piperacillin-susceptible organisms and piperacillin-resistant, β-lactamase producing organisms susceptible to ZOSYN should not require the addition of another antibiotic. (See <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>ZOSYN is useful as presumptive therapy in the indicated conditions prior to the identification of causative organisms because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic organisms.</p>
<p>Appropriate cultures should usually be performed before initiating antimicrobial treatment in order to isolate and identify the organisms causing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and to determine their susceptibility to ZOSYN. Antimicrobial therapy should be adjusted, if appropriate, once the results of culture(s) and antimicrobial susceptibility testing are known.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZOSYN (piperacillin and tazobactam) injection and other antibacterial drugs, ZOSYN (piperacillin and tazobactam) should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ZOSYN is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to any of the penicillins, cephalosporins, or β-lactamase inhibitors.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">SERIOUS AND OCCASIONALLY FATAL <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> (ANAPHYLACTIC/ANAPHYLACTOID) REACTIONS (INCLUDING <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">SHOCK</span>) HAVE BEEN REPORTED IN PATIENTS RECEIVING THERAPY WITH PENICILLINS INCLUDING ZOSYN. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH ZOSYN, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> OCCURS, ZOSYN SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED. <span class="Bold">SERIOUS ANAPHYLACTIC/ <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">ANAPHYLACTOID REACTIONS</span> (INCLUDING <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">SHOCK</span>) REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED</span>.</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including ZOSYN, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
<p>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, have been reported in patients receiving ZOSYN (see <span class="Bold"><a href="#adverse">ADVERSE REACTIONS</a></span>). If patients develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> they should be monitored closely and ZOSYN discontinued if lesions progress.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="general"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> manifestations have occurred in some patients receiving β-lactam antibiotics, including piperacillin. These reactions have sometimes been associated with abnormalities of coagulation tests such as clotting time, platelet aggregation, and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, and are more likely to occur in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> manifestations occur, ZOSYN (piperacillin and tazobactam for injection, USP) should be discontinued and appropriate therapy instituted.</p>
<p>The possibility of the emergence of resistant organisms that might cause <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> should be kept in mind. If this occurs, appropriate measures should be taken.</p>
<p>As with other penicillins, patients may experience neuromuscular <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> if higher than recommended doses are given intravenously (particularly in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>).</p>
<p>ZOSYN is a monosodium salt of piperacillin and a monosodium salt of tazobactam and contains a total of 2.79 mEq (64 mg) of Na<span class="Sup">+</span> per gram of piperacillin in the combination product. This should be considered when treating patients requiring restricted salt intake. Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics.</p>
<p>As with other semisynthetic penicillins, piperacillin therapy has been associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients.</p>
<p>In patients with creatinine clearance ≤ 40 mL/min and dialysis patients (hemodialysis and CAPD), the intravenous dose should be adjusted to the degree of renal function impairment. (See <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>Prescribing ZOSYN (piperacillin and tazobactam) in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="patientinfo"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs, including ZOSYN, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When ZOSYN is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ZOSYN or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="labtest"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Periodic assessment of hematopoietic function should be performed, especially with prolonged therapy, i.e., ≥ 21 days. (See <span class="Bold"><a href="#adverselab">ADVERSE REACTIONS, Adverse Laboratory Events</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="druginteractions"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.1"></a><p></p>
<h3>Aminoglycosides</h3>
<p class="First">The mixing of beta-lactam antibiotics with aminoglycosides <span class="Italics">in vitro</span> can result in substantial inactivation of the aminoglycoside. However, amikacin and gentamicin have been shown to be compatible <span class="Italics">in vitro</span> with reformulated ZOSYN containing EDTA supplied in vials or bulk pharmacy containers in certain diluents at specific concentrations for a simultaneous Y-site infusion. (See <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>.) Reformulated ZOSYN containing EDTA is not compatible with tobramycin for simultaneous co-administration via Y-site infusion.</p>
<p>The inactivation of aminoglycosides in the presence of penicillin-class drugs has been recognized. It has been postulated that penicillin-aminoglycoside complexes form; these complexes are microbiologically inactive and of unknown toxicity. Sequential administration of ZOSYN with tobramycin to patients with normal renal function and mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been shown to modestly decrease serum concentrations of tobramycin but does not significantly affect tobramycin pharmacokinetics. When aminoglycosides are administered in combination with piperacillin to patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring hemodialysis, the concentrations of the aminoglycosides (especially tobramycin) may be significantly altered and should be monitored. Since aminoglycosides are not equally susceptible to inactivation by piperacillin, consideration should be given to the choice of the aminoglycoside when administered in combination with piperacillin to these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.2"></a><p></p>
<h3>Probenecid</h3>
<p class="First">Probenecid administered concomitantly with ZOSYN prolongs the half-life of piperacillin by 21% and of tazobactam by 71%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.3"></a><p></p>
<h3>Vancomycin</h3>
<p class="First">No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> have been noted between ZOSYN and vancomycin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.4"></a><p></p>
<h3>Heparin</h3>
<p class="First">Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.5"></a><p></p>
<h3>Vecuronium</h3>
<p class="First">Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> of vecuronium. ZOSYN (piperacillin/tazobactam) could produce the same phenomenon if given along with vecuronium. Due to their similar mechanism of action, it is expected that the <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin. (See package insert for vecuronium bromide.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.6"></a><p></p>
<h3>Methotrexate</h3>
<p class="First">Limited data suggests that co-administration of methotrexate and piperacillin may reduce the clearance of methotrexate due to competition for renal secretion. The impact of tazobactam on the elimination of methotrexate has not been evaluated. If concurrent therapy is necessary, serum concentrations of methotrexate as well as the signs and symptoms of methotrexate toxicity should be frequently monitored.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="druglabtest"></a><a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">As with other penicillins, the administration of ZOSYN (piperacillin and tazobactam for injection, USP) may result in a false-positive reaction for glucose in the urine using a copper-reduction method (CLINITEST<span class="Sup">®</span>). It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as DIASTIX<span class="Sup">®</span> or TES-TAPE) be used.</p>
<p>There have been reports of positive test results using the Bio-Rad Laboratories Platelia <span class="Italics">Aspergillus</span> EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of <span class="Italics">Aspergillus</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Cross-reactions with non-<span class="Italics">Aspergillus</span> polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia <span class="Italics">Aspergillus</span> EIA test have been reported.</p>
<p>Therefore, positive test results in patients receiving piperacillin/tazobactam should be interpreted cautiously and confirmed by other diagnostic methods.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies in animals have not been conducted with piperacillin/tazobactam, piperacillin, or tazobactam.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.1"></a><p></p>
<h3>Piperacillin/Tazobactam</h3>
<p class="First">Piperacillin/tazobactam was negative in microbial mutagenicity assays at concentrations up to 14.84/1.86 μg/plate. Piperacillin/tazobactam was negative in the unscheduled DNA synthesis (UDS) test at concentrations up to 5689/711 μg/mL. Piperacillin/tazobactam was negative in a mammalian point mutation (Chinese hamster ovary cell HPRT) assay at concentrations up to 8000/1000 μg/mL. Piperacillin/tazobactam was negative in a mammalian cell (BALB/c-3T3) transformation assay at concentrations up to 8/1 μg/mL. <span class="Italics">In vivo</span>, piperacillin/tazobactam did not induce chromosomal aberrations in rats dosed I.V. with 1500/187.5 mg/kg; this dose is similar to the maximum recommended human daily dose on a body-surface-area basis (mg/m<span class="Sup">2</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.2"></a><p></p>
<h3>Piperacillin</h3>
<p class="First">Piperacillin was negative in microbial mutagenicity assays at concentrations up to 50 μg/plate. There was no DNA damage in bacteria (Rec assay) exposed to piperacillin at concentrations up to 200 μg/disk. Piperacillin was negative in the UDS test at concentrations up to 10,000 μg/mL. In a mammalian point mutation (mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells) assay, piperacillin was positive at concentrations ≥2500 μg/mL. Piperacillin was negative in a cell (BALB/c-3T3) transformation assay at concentrations up to 3000 μg/mL. <span class="Italics">In vivo</span>, piperacillin did not induce chromosomal aberrations in mice at I.V. doses up to 2000 mg/kg/day or rats at I.V. doses up to 1500 mg/kg/day. These doses are half (mice) or similar (rats) to the maximum recommended human daily dose based on body-surface area (mg/m<span class="Sup">2</span>). In another <span class="Italics">in vivo</span> test, there was no dominant lethal effect when piperacillin was administered to rats at I.V. doses up to 2000 mg/kg/day, which is similar to the maximum recommended human daily dose based on body-surface area (mg/m<span class="Sup">2</span>). When mice were administered piperacillin at I.V. doses up to 2000 mg/kg/day, which is half the maximum recommended human daily dose based on body-surface area (mg/m<span class="Sup">2</span>), urine from these animals was not mutagenic when tested in a microbial mutagenicity assay. Bacteria injected into the peritoneal cavity of mice administered piperacillin at I.V. doses up to 2000 mg/kg/day did not show increased mutation frequencies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.3"></a><p></p>
<h3>Tazobactam</h3>
<p class="First">Tazobactam was negative in microbial mutagenicity assays at concentrations up to 333 μg/plate. Tazobactam was negative in the UDS test at concentrations up to 2000 μg/mL. Tazobactam was negative in a mammalian point mutation (Chinese hamster ovary cell HPRT) assay at concentrations up to 5000 μg/mL. In another mammalian point mutation (mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells) assay, tazobactam was positive at concentrations ≥3000 μg/mL. Tazobactam was negative in a cell (BALB/c-3T3) transformation assay at concentrations up to 900 μg/mL. In an <span class="Italics">in vitro</span> cytogenetics (Chinese hamster lung cells) assay, tazobactam was negative at concentrations up to 3000 μg/mL. <span class="Italics">In vivo</span>, tazobactam did not induce chromosomal aberrations in rats at I.V. doses up to 5000 mg/kg, which is 23 times the maximum recommended human daily dose based on body-surface area (mg/m<span class="Sup">2</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.7.1"></a><p></p>
<h3>Teratogenic effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.1.1"></a><p></p>
<h5>Piperacillin/tazobactam</h5>
<p class="First">Reproduction studies have been performed in rats and have revealed no evidence of impaired fertility due to piperacillin/tazobactam administered up to a dose which is similar to the maximum recommended human daily dose based on body-surface area (mg/m<span class="Sup">2</span>).</p>
<p>Teratology studies have been performed in mice and rats and have revealed no evidence of harm to the fetus due to piperacillin/tazobactam administered up to a dose which is 1 to 2 times and 2 to 3 times the human dose of piperacillin and tazobactam, respectively, based on body-surface area (mg/m<span class="Sup">2</span>).</p>
<p>Piperacillin and tazobactam cross the placenta in humans.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.1.2"></a><p></p>
<h5>Piperacillin</h5>
<p class="First">Reproduction and teratology studies have been performed in mice and rats and have revealed no evidence of impaired fertility or harm to the fetus due to piperacillin administered up to a dose which is half (mice) or similar (rats) to the maximum recommended human daily dose based on body-surface area (mg/m<span class="Sup">2</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.1.3"></a><p></p>
<h5>Tazobactam</h5>
<p class="First">Reproduction studies have been performed in rats and have revealed no evidence of impaired fertility due to tazobactam administered at doses up to 3 times the maximum recommended human daily dose based on body-surface area (mg/m<span class="Sup">2</span>).</p>
<p>Teratology studies have been performed in mice and rats and have revealed no evidence of harm to the fetus due to tazobactam administered at doses up to 6 and 14 times, respectively, the human dose based on body-surface area (mg/m<span class="Sup">2</span>). In rats, tazobactam crosses the placenta. Concentrations in the fetus are less than or equal to 10% of those found in maternal plasma.</p>
<p>There are, however, no adequate and well-controlled studies with the piperacillin/tazobactam combination or with piperacillin or tazobactam alone in pregnant women. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Piperacillin is excreted in low concentrations in human milk; tazobactam concentrations in human milk have not been studied. Caution should be exercised when ZOSYN (piperacillin and tazobactam for injection, USP) is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatric"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Use of ZOSYN in pediatric patients 2 months of age or older with <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and/or <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> is supported by evidence from well-controlled studies and pharmacokinetic studies in adults and in pediatric patients. This includes a prospective, randomized, comparative, open-label clinical trial with 542 pediatric patients 2–12 years of age with complicated intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span>, in which 273 pediatric patients received piperacillin/tazobactam. Safety and efficacy in pediatric patients less than 2 months of age have not been established (see <span class="Bold"><a href="#clinpharm">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>There are no dosage recommendations for ZOSYN in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Patients over 65 years are <span class="Bold Underline">not</span> at an increased risk of developing adverse effects solely because of age. However, dosage should be adjusted in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. (See <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>ZOSYN contains 64 mg (2.79 mEq) of sodium per gram of piperacillin in the combination product. At the usual recommended doses, patients would receive between 768 and 1024 mg/day (33.5 and 44.6 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="adverseclin"></a><a name="section-8.1"></a><p></p>
<h2>Adverse Events From Clinical Trials</h2>
<p class="First">During the initial clinical investigations, 2621 patients worldwide were treated with ZOSYN (piperacillin and tazobactam for injection, USP) in phase 3 trials. In the key North American clinical trials (n=830 patients), 90% of the adverse events reported were mild to moderate in severity and transient in nature. However, in 3.2% of the patients treated worldwide, ZOSYN was discontinued because of adverse events primarily involving the skin (1.3%), including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; the gastrointestinal system (0.9%), including <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (0.5%).</p>
<p>Adverse local reactions that were reported, irrespective of relationship to therapy with ZOSYN, were <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> (1.3%), <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span> (0.5%), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (0.2%), <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (0.2%), <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> (0.2%), and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (0.1%).</p>
<p>Based on patients from the North American trials (n=1063), the events with the highest incidence in patients, irrespective of relationship to ZOSYN therapy, were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (11.3%); <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (7.7%); <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (7.7%); <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (6.9%); <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (6.6%); <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (4.2%), including maculopapular, bullous, urticarial, and eczematoid; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3.3%); <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (3.3%); <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (3.1%); stool changes (2.4%); <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (2.4%); <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> (2.1%); <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (1.7%); <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> (1.6%); <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (1.6%); <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (1.4%); <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (1.3%); <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (1.3%); <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (1.2%); <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (1.2%); <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (1.2%); and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (1.1%).</p>
<p>Additional adverse systemic clinical events reported in 1.0% or less of the patients in the initial North American trials are listed below within each body system.</p>
<p><span class="Italics">Autonomic nervous system</span>—<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></p>
<p><span class="Italics">Body as a whole</span>—<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
<p><span class="Italics">Cardiovascular</span>—<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, including supraventricular and ventricular; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, including <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">circulatory failure</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></p>
<p><span class="Italics">Central nervous system</span>—<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics">Gastrointestinal</span>—<span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccough</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> was reported in one patient during the clinical trials. The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment. (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>.)</p>
<p><span class="Italics">Hearing and Vestibular system</span>—<span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span>—<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span></p>
<p><span class="Italics">Metabolic and Nutritional</span>—symptomatic <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p>
<p><span class="Italics">Musculoskeletal</span>—<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></p>
<p><span class="Italics">Platelets, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, Clotting</span>—mesenteric <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (see <span class="Bold"><a href="#general">PRECAUTIONS, General</a></span>.)</p>
<p><span class="Italics">Psychiatric</span>—<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></p>
<p><span class="Italics">Reproductive, Female</span>—<span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span></p>
<p><span class="Italics">Respiratory</span>—<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span></p>
<p><span class="Italics">Skin and Appendages</span>—<span class="product-label-link" type="condition" conceptid="4146239" conceptname="Pruritus of genital organs">genital pruritus</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span></p>
<p><span class="Italics">Special senses</span>—<span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span></p>
<p><span class="Italics">Urinary</span>—retention, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span></p>
<p><span class="Italics">Vision</span>—<span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span></p>
<p><span class="Italics">Vascular (extracardiac)</span>—<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span> Trials</h3>
<p class="First">In a completed study of nosocomial <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span>, 222 patients were treated with ZOSYN in a dosing regimen of 4.5 g every 6 hours in combination with an aminoglycoside and 215 patients were treated with imipenem/cilastatin (500 mg/500 mg q6h) in combination with an aminoglycoside. In this trial, treatment-emergent adverse events were reported by 402 patients, 204 (91.9%) in the piperacillin/tazobactam group and 198 (92.1%) in the imipenem/cilastatin group. Twenty-five (11.0%) patients in the piperacillin/tazobactam group and 14 (6.5%) in the imipenem/cilastatin group (p &gt; 0.05) discontinued treatment due to an adverse event.</p>
<p>In this study of ZOSYN in combination with an aminoglycoside, adverse events that occurred in more than 1% of patients and were considered by the investigator to be drug-related were: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (17.6%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (2.7%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2.7%), <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (2.7%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (2.3%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (1.8%), <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span> (1.8%), <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> (1.8%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.8%), <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span> (1.8%), BUN increased (1.8%), creatinine increased (1.8%), <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (1.8%), <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdomen enlarged</span> (1.4%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (1.4%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (1.4%), <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function tests abnormal</span> (1.4%), <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocythemia</span> (1.4%), <span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">excoriations</span> (1.4%), and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (1.4%).</p>
<p>Drug-related adverse events reported in 1% or less of patients in the <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> study of ZOSYN with an aminoglycoside were: <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute kidney failure</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, alkaline phosphatase increased, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, drug level decreased, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal convulsion</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">hypochromic anemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4319319" conceptname="Injection site edema">injection site edema</span>, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">kidney function abnormal</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, local reaction to procedure, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> decreased, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased, SGPT increased, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>, and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>.</p>
<p>In a previous <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> study conducted with a dosing regimen of 3.375 g given every 4 hours with an aminoglycoside, the following adverse events, irrespective of drug relationship, were observed: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (20%); <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (8.4%); <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> (7.1%); <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5.8%); <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (4.5%); <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (4.5%); <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral thrush</span> (3.9%); erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (3.9%); <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (3.2%); <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (3.2%); <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (3.2%); <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (3.2%); <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccough</span> (2.6%); <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2.6%); <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (1.9%); <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (1.9%); <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> (1.9%); stool changes (1.9%); <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (1.3%); <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (1.3%); <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> (1.3%); <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> (1.3%); <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (1.3%); <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> (1.3%); <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (1.3%); <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (1.3%); <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> at injection site (1.3%); <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> (1.3%); <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span> (1.3%); <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, not otherwise specified (1.3%); <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> (1.3%); <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> (1.3%); and <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span> (1.3%).</p>
<p>Adverse events irrespective of drug relationship observed in 1% or less of patients in the above study with ZOSYN and an aminoglycoside included: <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span> (combative), angina, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="261880" conceptname="Atelectasis">atelectasis</span>, <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, perineal irritation/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> with trichomonas, vitamin B<span class="Sub">12</span> <span class="product-label-link" type="condition" conceptid="4280354" conceptname="Nutritional anemia">deficiency anemia</span>, xerosis, and yeast in urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<h3>Pediatrics</h3>
<p class="First">Studies of ZOSYN in pediatric patients suggest a similar safety profile to that seen in adults. In a prospective, randomized, comparative, open-label clinical trial of pediatric patients with severe intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> (including <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and/or <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>), 273 patients were treated with ZOSYN (112.5 mg/kg every 8 hours) and 269 patients were treated with cefotaxime (50 mg/kg) plus metronidazole (7.5 mg/kg) every 8 hours. In this trial, treatment-emergent adverse events were reported by 146 patients, 73 (26.7%) in the ZOSYN group and 73 (27.1%) in the cefotaxime/metronidazole group. Six patients (2.2%) in the ZOSYN group and 5 patients (1.9%) in the cefotaxime/metronidazole group discontinued due to an adverse event.</p>
<p>In this study, adverse events that were reported in more than 1% of patients, irrespective of relationship to therapy with ZOSYN, were: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (7.0%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (4.8%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3.7%), local reaction (3.3%), <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> (2.2%), <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (2.2%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (1.8%), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (1.8%), <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> (1.1%), <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (1.5%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (1.1%), and <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increase (1.1%).</p>
<p>Adverse events reported in 1% or less of pediatric patients receiving ZOSYN are consistent with adverse events reported in adults.</p>
<p>Additional controlled studies in pediatric patients showed a similar safety profile as that described above.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3"></a><p></p>
<h3>Post-Marketing Experience</h3>
<p class="First">Additional adverse events reported from worldwide marketing experience with ZOSYN, occurring under circumstances where causal relationship to ZOSYN is uncertain:</p>
<p><span class="Italics">Gastrointestinal</span>—<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span></p>
<p><span class="Italics">Hematologic</span>—<span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span></p>
<p><span class="Italics">Immune</span>––<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>)</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span>––candidal <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span></p>
<p><span class="Italics">Renal</span>—interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></p>
<p><span class="Italics">Skin and Appendages</span>—<span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></p>
<p>Post-marketing experience with ZOSYN in pediatric patients suggests a similar safety profile to that seen in adults.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="adverselab"></a><a name="section-8.2"></a><p></p>
<h2>Adverse Laboratory Events (Seen During Clinical Trials)</h2>
<p class="First">Of the studies reported, including that of nosocomial <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span> in which a higher dose of ZOSYN (piperacillin and tazobactam for injection, USP) was used in combination with an aminoglycoside, changes in laboratory parameters, without regard to drug relationship, include:</p>
<p><span class="Italics">Hematologic</span>—decreases in hemoglobin and hematocrit, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, increases in platelet count, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. The <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> associated with ZOSYN administration appears to be reversible and most frequently associated with prolonged administration, i.e., ≥ 21 days of therapy. These patients were withdrawn from therapy; some had accompanying systemic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>).</p>
<p><span class="Italics">Coagulation</span>—positive direct Coombs' test, prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, prolonged partial thromboplastin time</p>
<p><span class="Italics">Hepatic</span>—transient elevations of AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), ALT (SGPT), alkaline phosphatase, bilirubin</p>
<p><span class="Italics">Renal</span>—increases in serum creatinine, blood urea nitrogen</p>
<p><span class="Italics">Urinalysis</span>—<span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">pyuria</span></p>
<p>Additional laboratory events include abnormalities in electrolytes (i.e., increases and decreases in sodium, potassium, and calcium), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, decreases in total protein or albumin, blood glucose decreased, gamma-glutamyltransferase increased, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> prolonged.</p>
<p>The following adverse reaction has also been reported for PIPRACIL<span class="Sup">®</span> (piperacillin for injection):</p>
<p><span class="Italics">Skeletal</span>—prolonged <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> (See <span class="Bold"><a href="#druginteractions">PRECAUTIONS, Drug Interactions</a></span>.)</p>
<p>Piperacillin therapy has been associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="overdosage"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with piperacillin/tazobactam. The majority of those events experienced, including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, have also been reported with the usual recommended dosages. Patients may experience neuromuscular <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> if higher than recommended doses are given intravenously (particularly in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>).</p>
<p>Treatment should be supportive and symptomatic according to the patient's clinical presentation. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by hemodialysis. Following a single 3.375 g dose of piperacillin/tazobactam, the percentage of piperacillin and tazobactam dose removed by hemodialysis was approximately 31% and 39%, respectively. (See <span class="Bold"><a href="#clinpharm">CLINICAL PHARMACOLOGY</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="doseadmin"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">ZOSYN should be administered by intravenous infusion over 30 minutes.</p>
<p>The usual daily dose of ZOSYN for adults is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></h2>
<p class="First">Initial presumptive treatment of patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> should start with ZOSYN at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam). Treatment with the aminoglycoside should be continued in patients from whom <span class="Italics">Pseudomonas aeruginosa</span> is isolated. If <span class="Italics">Pseudomonas aeruginosa</span> is not isolated, the aminoglycoside may be discontinued at the discretion of the treating physician.</p>
<p>Due to the <span class="Italics">in vitro</span> inactivation of the aminoglycoside by beta-lactam antibiotics, ZOSYN and the aminoglycoside are recommended for separate administration. ZOSYN and the aminoglycoside should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated. (See <span class="Bold"><a href="#druginteractions">PRECAUTIONS, Drug Interactions</a></span>.)</p>
<p>In circumstances where co-administration via Y-site is necessary, reformulated ZOSYN containing EDTA supplied in vials or bulk pharmacy containers is compatible for simultaneous coadministration via Y-site infusion only with the following aminoglycosides under the following conditions:</p>
<p><span class="Bold">The following compatibility information does not apply to the ZOSYN (piperacillin/tazobactam) formulation not containing EDTA. This information does not apply to ZOSYN in Galaxy<span class="Sup">®</span> containers. Refer to the package insert for ZOSYN Galaxy containers for instructions.</span></p>
<a name="table4"></a><table width="75%">
<caption><span>TABLE 4</span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Aminoglycoside</th>
<th class="Rrule" align="center">ZOSYN Dose<br>(grams)</th>
<th class="Rrule" align="center">ZOSYN Diluent Volume<br>(mL)</th>
<th class="Rrule" align="center">Aminoglycoside Concentration Range<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a><br>(mg/mL)</th>
<th class="Rrule" align="center">Acceptable Diluents</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>The concentration ranges in Table 4 are based on administration of the aminoglycoside in divided doses (10–15 mg/kg/day in two daily doses for amikacin and 3–5 mg/kg/day in three daily doses for gentamicin). Administration of amikacin or gentamicin in a single daily dose or in doses exceeding those stated above via Y-site with ZOSYN containing EDTA has not been evaluated. See package insert for each aminoglycoside for complete Dosage and Administration instructions.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Amikacin</td>
<td class="Rrule" align="center">2.25, 3.375, 4.5</td>
<td class="Rrule" align="center">50, 100, 150</td>
<td class="Rrule" align="center">1.75 – 7.5</td>
<td class="Rrule" align="center">0.9% Sodium Chloride or 5% Dextrose</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Gentamicin</td>
<td class="Rrule" align="center">2.25, 3.375, 4.5</td>
<td class="Rrule" align="center">50, 100, 150</td>
<td class="Rrule" align="center">0.7 – 3.32</td>
<td class="Rrule" align="center">0.9% Sodium Chloride or 5% Dextrose</td>
</tr>
</tbody>
</table>
<p><span class="Bold">ZOSYN is not compatible with tobramycin for simultaneous coadministration via Y-site infusion. Compatibility of ZOSYN with other aminoglycosides has not been established. Only the concentration and diluents for amikacin or gentamicin with the dosages of ZOSYN listed above have been established as compatible for coadministration via Y-site infusion. Simultaneous coadministration via Y-site infusion in any manner other than listed above may result in inactivation of the aminoglycoside by ZOSYN.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (Creatinine Clearance ≤ 40 mL/min), the intravenous dose of ZOSYN (piperacillin and tazobactam for injection, USP) should be adjusted to the degree of actual renal function impairment. In patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> receiving concomitant aminoglycoside therapy, the aminoglycoside dosage should be adjusted according to the recommendations of the manufacturer. The recommended daily doses of ZOSYN for patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> are as follows:</p>
<table width="75%">
<caption><span>Recommended Dosing of ZOSYN in Patients with Normal Renal Function and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span> (As total grams piperacillin/tazobactam)</span></caption>
<col align="center" valign="bottom" width="30%">
<col align="center" valign="bottom" width="40%">
<col align="center" valign="bottom" width="30%">
<thead><tr class="First Last">
<th align="center">Renal Function<br>(Creatinine Clearance, mL/min)</th>
<th align="center">All Indications (except <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span>)</th>
<th align="center"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>Creatinine clearance for patients not receiving hemodialysis</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
<dd>0.75 g should be administered following each hemodialysis session on hemodialysis days</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center">&gt;40 mL/min</td>
<td align="center">3.375 q 6 h</td>
<td align="center">4.5 q 6 h</td>
</tr>
<tr>
<td align="center">20–40 mL/min<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a>
</td>
<td align="center">2.25 q 6 h</td>
<td align="center">3.375 q 6 h</td>
</tr>
<tr>
<td align="center">&lt;20 mL/min<a href="#footnote-10" class="Sup">*</a>
</td>
<td align="center">2.25 q 8 h</td>
<td align="center">2.25 q 6 h</td>
</tr>
<tr>
<td align="center">Hemodialysis<a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a>
</td>
<td align="center">2.25 q 12 h</td>
<td align="center">2.25 q 8 h</td>
</tr>
<tr class="Last">
<td align="center">CAPD</td>
<td align="center">2.25 q 12 h</td>
<td align="center">2.25 q 8 h</td>
</tr>
</tbody>
</table>
<p>For patients on hemodialysis, the maximum dose is 2.25 g every twelve hours for all indications other than <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> and 2.25 g every eight hours for <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span>. Since hemodialysis removes 30% to 40% of the administered dose, an additional dose of 0.75 g ZOSYN should be administered following each dialysis period on hemodialysis days. No additional dosage of ZOSYN is necessary for CAPD patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Duration of Therapy</h2>
<p class="First">The usual duration of ZOSYN treatment is from seven to ten days. However, the recommended duration of ZOSYN treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> is 7 to 14 days. In all conditions, the duration of therapy should be guided by the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the patient's clinical and bacteriological progress.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">For children with <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and/or <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> 9 months of age or older, weighing up to 40 kg, and with normal renal function, the recommended ZOSYN dosage is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight, every 8 hours. For pediatric patients between 2 months and 9 months of age, the recommended ZOSYN dosage based on pharmacokinetic modeling, is 80 mg piperacillin/10 mg tazobactam per kilogram of body weight, every 8 hours (see <span class="Bold"><a href="#general">PRECAUTIONS, General</a>, <a href="#pediatric">Pediatric Use</a></span> and <span class="Bold"><a href="#clinpharm">CLINICAL PHARMACOLOGY</a></span>). Pediatric patients weighing over 40 kg and with normal renal function should receive the adult dose. There are no dosage recommendations for ZOSYN in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5"></a><p></p>
<h2>Directions for Reconstitution and Dilution for Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.1"></a><p></p>
<h3>Intravenous Administration</h3>
<table width="50%">
<col align="center" valign="top" width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule" align="center"><span class="Bold">Pharmacy Bulk Package<br>Not for Direct Infusion</span></td></tr></tbody>
</table>
<p class="First"><span class="Bold">RECONSTITUTED STOCK SOLUTION MUST BE TRANSFERRED AND FURTHER DILUTED FOR I.V. INFUSION</span></p>
<p>The pharmacy bulk vial is for use in a hospital pharmacy admixture service only under a laminar flow hood. After reconstitution, entry into the vial must be made with a sterile transfer set or other sterile dispensing device, and contents should be dispensed as aliquots into intravenous solution using aseptic technique. Use entire contents of pharmacy bulk vial promptly. Discard unused portion after 24 hours if stored at room temperature (20°C to 25°C [68°F to 77°F]), or after 48 hours if stored at refrigerated temperature (2°C to 8°C [36°F to 46°F]).</p>
<p>Reconstitute the pharmacy bulk vial with exactly 152 mL of a compatible reconstitution diluent, listed below, to a concentration of 200 mg/mL of piperacillin and 25 mg/mL of tazobactam. Shake well until dissolved. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to and during administration whenever solution and container permit.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.1.1"></a><p></p>
<h4>Compatible Reconstitution Diluents</h4>
<p class="First">0.9% Sodium Chloride for Injection<br>Sterile Water for Injection<a name="footnote-reference-12" href="#footnote-12" class="Sup">2</a><br>Dextrose 5%<br>Bacteriostatic Saline/Parabens<br>Bacteriostatic Water/Parabens<br>Bacteriostatic Saline/Benzyl Alcohol<br>Bacteriostatic Water/Benzyl Alcohol</p>
<p>Reconstituted ZOSYN solution should be further diluted (recommended volume per dose of 50 mL to 150 mL) in a compatible intravenous solution listed below. Administer by infusion over a period of at least 30 minutes. During the infusion it is desirable to discontinue the primary infusion solution.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">2</a></dt>
<dd>Maximum recommended volume per dose of Sterile Water for Injection is 50 mL.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.1.2"></a><p></p>
<h4>Compatible Intravenous Solutions</h4>
<p class="First">0.9% Sodium Chloride for Injection<br>Sterile Water for Injection<a href="#footnote-12" class="Sup">2</a><br>Dextran 6% in Saline<br>Dextrose 5%<br>Lactated Ringer's Solution (Compatible <span class="Bold">only</span> with reformulated ZOSYN containing EDTA and is compatible for co-administration via a Y-site).</p>
<p>ZOSYN should not be mixed with other drugs in a syringe or infusion bottle since compatibility has not been established.</p>
<p>ZOSYN is not chemically stable in solutions that contain only sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and solutions that significantly alter the pH.</p>
<p>ZOSYN should not be added to blood products or albumin hydrolysates.</p>
<p>ZOSYN can be used in ambulatory intravenous infusion pumps.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.1.3"></a><p></p>
<h4>Stability of ZOSYN Following Reconstitution</h4>
<p class="First">ZOSYN is stable in glass and plastic containers (plastic syringes, I.V. bags, and tubing) when used with compatible diluents.</p>
<p>The pharmacy bulk vial should <span class="Bold">NOT</span> be frozen after reconstitution. Discard unused portions after storage for 24 hours at room temperature (20°C to 25°C [68°F to 77°F]) or after storage for 48 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]).</p>
<p>Stability studies in the I.V. bags have demonstrated chemical stability [potency, pH of reconstituted solution, and clarity of solution] for up to 24 hours at room temperature and up to one week at refrigerated temperature. ZOSYN contains no preservatives. Appropriate consideration of aseptic technique should be used.</p>
<p>Stability of ZOSYN (piperacillin and tazobactam for injection, USP) in an ambulatory intravenous infusion pump has been demonstrated for a period of 12 hours at room temperature. Each dose was reconstituted and diluted to a volume of 37.5 mL or 25 mL. One-day supplies of dosing solution were aseptically transferred into the medication reservoir (I.V. bags or cartridge). The reservoir was fitted to a preprogrammed ambulatory intravenous infusion pump per the manufacturer's instructions. Stability of ZOSYN is not affected when administered using an ambulatory intravenous infusion pump.</p>
<p>Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ZOSYN (piperacillin and tazobactam for injection, USP) is supplied as a powder in the pharmacy bulk vial as follows:</p>
<p>Each ZOSYN 40.5 g pharmacy bulk vial contains piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 grams tazobactam, 9 mg of edetate disodium dihydrate (EDTA), and 1800 mg of sodium citrate. Each pharmacy bulk vial contains 100.4 mEq (2,304 mg) of sodium.</p>
<p>NDC 0206-5501-01</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">ZOSYN (piperacillin and tazobactam for injection, USP) pharmacy bulk vials should be stored at controlled room temperature 20°C to 25°C (68°F to 77°F) prior to reconstitution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Also Available</h2>
<p class="First">ZOSYN (piperacillin and tazobactam for injection, USP) is also supplied as follows:</p>
<p>2.25 g single-dose vial containing piperacillin sodium equivalent to 2 g of piperacillin and tazobactam sodium equivalent to 0.25 g of tazobactam. Each vial contains 5.58 mEq (128 mg) of sodium. Supplied as follows:</p>
<p>1 vial – NDC-0206-2501-01</p>
<p>10 vials in a carton - NDC-0206-2501-10</p>
<p>3.375 g single-dose vial containing piperacillin sodium equivalent to 3 g of piperacillin and tazobactam sodium equivalent to 0.375 g of tazobactam. Each vial contains 8.38 mEq (192 mg) of sodium. Supplied  as follows:</p>
<p>1 vial – NDC-0206-3501-01</p>
<p>10 vials in a carton - NDC-0206-3501-10</p>
<p>4.5 g single-dose vial containing piperacillin sodium equivalent to 4 g of piperacillin and tazobactam sodium equivalent to 0.5 g of tazobactam. Each vial contains 11.17 mEq (256 mg) of sodium. Supplied as follows:</p>
<p>1 vial – NDC-0206-4501-01</p>
<p>10 vials in a carton - NDC-0206-4501-10</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; 21<span class="Sup">st</span> Informational Supplement.  CLSI document M100-S21. CLSI, 940 West Valley Rd., Suite 1400, Wayne, PA 19087, 2011</li>
<li>CLSI. Methods for Dilution Antimicrobial Susceptibility Test for Bacteria that Grow Aerobically; Approved Standard – 8<span class="Sup">th</span> ed. CLSI document M07-A8, 2009.</li>
<li>CLSI. Performance Standards for Antimicrobial Disk Susceptibility Test; Approved Standard – 10<span class="Sup">th</span> ed. CLSI document M02-A10, 2009.</li>
<li>CLSI. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard – 7th ed. CLSI document M11-A7, 2007.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">DIASTIX<span class="Sup">®</span> is a registered trademark of Bayer Healthcare LLC.</p>
<p>CLINITEST<span class="Sup">®</span> is a registered trademark of Siemens Healthcare Diagnostics Inc.</p>
<table width="100%">
<col align="center" valign="top" width="10%">
<col align="left" valign="top" width="80%">
<col align="center" valign="top" width="10%">
<tbody class="Headless"><tr class="First Last">
<td align="center"><img alt="Computer" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81b0bb45-ce9d-43e7-b181-64315e14be55&amp;name=zosyn-03.jpg"></td>
<td align="left">This product's label may have been updated. For current package insert and further product information, please visit www.pfizer.com or call our medical communications department toll-free at 1-800-438-1985.</td>
<td align="center"><img alt="Phone" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81b0bb45-ce9d-43e7-b181-64315e14be55&amp;name=zosyn-04.jpg"></td>
</tr></tbody>
</table>
<p>Distributed by<br>Wyeth Pharmaceuticals Inc<br>A subsidiary of Pfizer Inc<br>Philadelphia, PA 19101</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81b0bb45-ce9d-43e7-b181-64315e14be55&amp;name=zosyn-05.jpg"></p>
<p>PREMIERPro™ Rx is a trademark of Premier, Inc., used under license.</p>
<p>LAB-0665-1.0</p>
<p>March 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 40.5 gram Vial Label</h1>
<p class="First"><span class="Bold">PREMIER</span>Pro™ Rx</p>
<p>NDC 0206-5501-01</p>
<p><span class="Bold">Zosyn</span><span class="Sup">®</span><br>(Piperacillin and Tazobactam<br>for Injection, USP)</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">40.5 gram vial</span></p>
<p><span class="Bold">PHARMACY BULK PACKAGE<br>Not for Direct Infusion</span></p>
<p>Distributed by Wyeth Pharmaceuticals Inc<br>A subsidiary of Pfizer Inc, Philadelphia, PA 19101</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 40.5 gram Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81b0bb45-ce9d-43e7-b181-64315e14be55&amp;name=zosyn-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 40.5 gram Vial Carton</h1>
<p class="First">NDC 0206-5501-01<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">Zosyn</span><span class="Sup">®</span><br>(Piperacillin and Tazobactam<br>for Injection, USP)</p>
<p><span class="Bold">40.5 gram vial</span></p>
<p><span class="Bold">PHARMACY BULK PACKAGE<br>Not for Direct Infusion</span></p>
<p>RECONSTITUTED STOCK SOLUTION MUST BE<br>TRANSFERRED AND FURTHER DILUTED<br>FOR I.V. INFUSION</p>
<p><span class="Bold">PREMIER</span>Pro™ Rx</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 40.5 gram Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=81b0bb45-ce9d-43e7-b181-64315e14be55&amp;name=zosyn-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOSYN  		
					PHARMACY BULK PACKAGE</strong><br><span class="contentTableReg">tazobactam sodium and piperacillin sodium injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0206-5501</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TAZOBACTAM SODIUM</strong> (TAZOBACTAM) </td>
<td class="formItem">TAZOBACTAM</td>
<td class="formItem">4.5 g  in 180 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PIPERACILLIN SODIUM</strong> (PIPERACILLIN ANHYDROUS) </td>
<td class="formItem">PIPERACILLIN ANHYDROUS</td>
<td class="formItem">36 g  in 180 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">9 mg  in 180 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0206-5501-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">180 mL in 1 VIAL, PHARMACY BULK PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050684</td>
<td class="formItem">06/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
							(828831441)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Wyeth Lederle S.R.L.</td>
<td class="formItem"></td>
<td class="formItem">542812040</td>
<td class="formItem">ANALYSIS(0206-5501), LABEL(0206-5501), MANUFACTURE(0206-5501), PACK(0206-5501)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a7cead9b-dcd0-415b-b4ba-19ed6b24f575</div>
<div>Set id: 81b0bb45-ce9d-43e7-b181-64315e14be55</div>
<div>Version: 2</div>
<div>Effective Time: 20131106</div>
</div>
</div> <div class="DistributorName">Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.</div></p>
</body></html>
